Researchers from the University of California San Diego and GlySens Inc. have developed an implantable sensor that measures blood sugar continuously and transmits the information without wires, according to a Reuters report . The device worked in one pig for more than a year and in another for nearly 10 months with no trouble, and the...

MannKind Corporation announced that it has submitted, and the U.S. Food and Drug Administration (FDA) has accepted, MannKind’s resubmission of its New Drug Application (NDA) for AFREZZA(TM) (insulin human [rDNA origin]) and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA...

Biodel Inc. reported results of preclinical tests which demonstrated the potential of the company’s glucose-regulated or “smart” basal insulin product candidate, BIOD620, to release insulin proportionally in response to changing glucose conditions. In an oral presentation today at the 37th Annual Meeting and Exposition...

Biodel Inc. announced the award of two research grants by the Juvenile Diabetes Research Foundation (JDRF) to Stanford University and Oregon Health & Science University (OHSU) to evaluate the use of VIAject(R) (ultra-rapid-acting injectable human insulin) in the treatment of diabetes. The first grant will support clinical testing...

According to a Novo Nordisk press release the company presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycemic control when used once daily or three times weekly. These data were presented at the 70th Scientific...

Eli Lilly and Company announced they’re teaming up with Walmart to provide an affordable insulin option for people with diabetes. Beginning in mid-September, Lilly’s Humulin(R) brand of insulin will be available in Walmart pharmacies across the U.S. under the dual-branded name Humulin(R) ReliOn(R), including 10 mL vials of...

MannKind  announced that results of a new 16-week trial show that the investigational ultra rapid acting mealtime insulin, AFREZZA (insulin human [rDNA origin]) Inhalation Powder, combined with basal insulin, is clearly non-inferior to standard therapy insulin lispro, a rapid acting insulin (also combined...

The American Diabetes Association (ADA) issued a statement expressing extreme disappointment in the California Court of Appeal ruling in the case of American Nurses Association et al. v. O’Connell, which prevents non-medical school personnel from volunteering to administer insulin to California schoolchildren who are not yet able...

Novo Nordisk has announced an online insulin pen photo contest.  The “Where Have You Flexed?” contest asks people who use the FlexPen to submit photos of themselves with their pen in unique locations.  The grand prize winner will receive a trip for two to the Firestone Indy Lights championship in Miami on October 2 to...

MannKind Corp. announced the results of a two year study comparing the efficacy and safety of AFREZZA (insulin human [rDNA origin]) versus usual diabetes care. The study followed patients for a total of up to two years. The patients were randomly assigned to a treatment regimen of either AFREZZA plus subcutaneous basal...